Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
cefalexin monohydrate, Quantity: 50 mg/mL (Equivalent: cefalexin monohydrate, Qty 52.576 mg/mL)
Arrotex Pharmaceuticals Pty Ltd
Suspension, powder for
Excipient Ingredients: citric acid; sucrose; iron oxide yellow; saccharin sodium; guar galactomannan; simethicone; sodium benzoate; Flavour
Oral
100mL
(S4) Prescription Only Medicine
Treatment of the following infections when caused by susceptible strains of the designated microorganisms. Respiratory tract infections. Caused by S. pneumoniae and group A beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). Bacterial sinusitis. Caused by streptococci, S. pneumoniae and S. aureus (methicillin sensitive only). Otitis media. Due to S. pneumoniae, staphylococci. Skin and skin structure infections. Caused by staphylococci and/or streptococci. Genitourinary tract infections, including acute prostatitis. Caused by E. coli, P. mirabilis, and klebsiella sp. The effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions. Note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. Renal function studies should be performed when indicated.
Visual Identification: Orange-yellow granules forming an orange-yellow suspension upon reconstitution with water; Container Type: Bottle; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Registered
2004-01-29